Wilbanks Smith & Thomas Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $427K | Buy |
+6,302
| New | +$427K | 0.01% | 369 |
|
|
2023
Q4 | – | Sell |
-2,960
| Closed | -$200K | – | 520 |
|
|
2023
Q3 | $200K | Sell |
2,960
-106
| -3% | -$7.18K | 0.01% | 481 |
|
|
2023
Q2 | $219K | Sell |
3,066
-143
| -4% | -$10.2K | 0.01% | 477 |
|
|
2023
Q1 | $223K | Sell |
3,209
-44
| -1% | -$3.05K | 0.01% | 469 |
|
|
2022
Q4 | $221K | Sell |
3,253
-750
| -19% | -$50.9K | 0.01% | 458 |
|
|
2022
Q3 | $220K | Buy |
4,003
+320
| +9% | +$17.6K | 0.01% | 423 |
|
|
2022
Q2 | $243K | Sell |
3,683
-62
| -2% | -$4.09K | 0.01% | 417 |
|
|
2022
Q1 | $252K | Sell |
3,745
-168
| -4% | -$11.3K | 0.01% | 431 |
|
|
2021
Q4 | $228K | Sell |
3,913
-36
| -0.9% | -$2.1K | 0.01% | 468 |
|
|
2021
Q3 | $237K | Buy |
+3,949
| New | +$237K | 0.01% | 444 |
|
|
2018
Q4 | – | Sell |
-921
| Closed | -$36K | – | 433 |
|
|
2018
Q3 | $36K | Buy |
+921
| New | +$36K | ﹤0.01% | 749 |
|